Healthcare -
Biotechnology - NASDAQ - US
$ 14.76
-7.49 %
$ 958 M
Market Cap
-3.95
P/E
1. INTRINSIC VALUE
Balance Sheet
Mineralys Therapeutics, Inc.
| Current Assets | 205 M |
| Cash & Short-Term Investments | 198 M |
| Receivables | 0 |
| Other Current Assets | 7.16 M |
| Non-Current Assets | 552 K |
| Long-Term Investments | 0 |
| PP&E | 53 K |
| Other Non-Current Assets | 499 K |
| Current Liabilities | 14.6 M |
| Accounts Payable | 479 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 14.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Mineralys Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 192 M |
| Operating Income | -192 M |
| Other Expenses | -14.6 M |
| Net Income | -178 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Mineralys Therapeutics, Inc.
| Net Income | -178 M |
| Depreciation & Amortization | 43 K |
| Capital Expenditures | -96 K |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | 9.52 M |
| Others | -307 K |
| Free Cash Flow | -166 M |
Wall Street Analysts Price Targets
Mineralys Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for MLYS of $42 , with forecasts ranging from
a
low of
$42 to a high of $42 .
MLYS Lowest Price Target
Wall Street Target
42 USD
184.55%
MLYS Average Price Target
Wall Street Target
42 USD
184.55%
MLYS Highest Price Target
Wall Street Target
42 USD
184.55%
4. DIVIDEND
ANALYSIS
MLYS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Mineralys Therapeutics, Inc.
Sold
0-3 MONTHS
1.36 M USD 3
3-6 MONTHS
264 K USD 2
6-9 MONTHS
811 K USD 3
9-12 MONTHS
10.3 M USD 4
Bought
37.2 M USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Mar 13, 2025
|
Bought
3.5 M USD
|
Slingsby Brian Taylor
director, 10 percent owner:
|
+ 259259
|
13.5 USD |
|
1 month ago
Apr 14, 2025
|
Sell 40.6 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 2966
|
13.6929 USD |
|
1 month ago
Apr 14, 2025
|
Sell 125 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 8400
|
14.83 USD |
|
1 month ago
Apr 11, 2025
|
Sell 130 K
USD
|
Levy Adam Scott
CFO and Secretary
|
- 10757
|
12.0558 USD |
|
1 month ago
Apr 11, 2025
|
Sell 187 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 15319
|
12.1942 USD |
|
1 month ago
Apr 01, 2025
|
Sell 459 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 30574
|
14.9978 USD |
|
1 month ago
Apr 01, 2025
|
Sell 44.7 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 2791
|
16.0219 USD |
|
1 month ago
Apr 01, 2025
|
Sell 376 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 22406
|
16.77 USD |
|
2 months ago
Mar 13, 2025
|
Bought
8.1 M USD
|
Samsara BioCapital GP, LLC
10 percent owner
|
+ 600000
|
13.5 USD |
|
2 months ago
Mar 13, 2025
|
Bought
8.1 M USD
|
AKKARAJU SRINIVAS
Director
|
+ 600000
|
13.5 USD |
|
2 months ago
Mar 13, 2025
|
Bought
17.5 M USD
|
RA CAPITAL MANAGEMENT, L.P.
Director
|
+ 1296296
|
13.5 USD |
|
4 months ago
Jan 13, 2025
|
Sell 96.9 K
USD
|
Levy Adam Scott
CFO and Secretary
|
- 10657
|
9.0927 USD |
|
4 months ago
Jan 13, 2025
|
Sell 963
USD
|
Levy Adam Scott
CFO and Secretary
|
- 100
|
9.63 USD |
|
4 months ago
Jan 13, 2025
|
Sell 166 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 18333
|
9.0592 USD |
|
6 months ago
Nov 11, 2024
|
Sell 75.4 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 5026
|
15.0016 USD |
|
6 months ago
Nov 06, 2024
|
Sell 383 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 25482
|
15.0328 USD |
|
7 months ago
Oct 11, 2024
|
Sell 146 K
USD
|
Levy Adam Scott
CFO and Secretary
|
- 10757
|
13.5729 USD |
|
7 months ago
Oct 11, 2024
|
Sell 206 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 15271
|
13.518 USD |
|
9 months ago
Jul 24, 2024
|
Sell 7.18 M
USD
|
Slingsby Brian Taylor
director, 10 percent owner:
|
- 550000
|
13.05 USD |
|
10 months ago
Jul 16, 2024
|
Sell 7.88 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 525
|
15.0011 USD |
|
10 months ago
Jul 11, 2024
|
Sell 141 K
USD
|
Levy Adam Scott
CFO and Secretary
|
- 10757
|
13.1444 USD |
|
10 months ago
Jul 11, 2024
|
Sell 210 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 15746
|
13.3415 USD |
|
11 months ago
Jun 17, 2024
|
Sell 218 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 17766
|
12.2544 USD |
|
11 months ago
Jun 18, 2024
|
Sell 199 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 16607
|
11.9873 USD |
|
11 months ago
Jun 20, 2024
|
Sell 175 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 14940
|
11.7294 USD |
|
11 months ago
Jun 12, 2024
|
Sell 212 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 16607
|
12.7665 USD |
|
11 months ago
Jun 13, 2024
|
Sell 509 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 39961
|
12.7381 USD |
|
11 months ago
Jun 14, 2024
|
Sell 203 K
USD
|
Congleton Jon
Chief Executive Officer
|
- 16229
|
12.5185 USD |
|
11 months ago
Jun 11, 2024
|
Sell 1.25 M
USD
|
Levy Adam Scott
CFO and Secretary
|
- 96815
|
12.9393 USD |
|
1 year ago
May 09, 2024
|
Sell 1.5 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 100
|
15 USD |
|
1 year ago
Feb 12, 2024
|
Bought
7.5 M USD
|
Samsara BioCapital GP, LLC
10 percent owner
|
+ 555555
|
13.5 USD |
|
1 year ago
Nov 22, 2023
|
Bought
25.4 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 4250
|
5.9661 USD |
|
1 year ago
Sep 06, 2023
|
Bought
27.2 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 2250
|
12.08 USD |
|
1 year ago
Aug 17, 2023
|
Bought
27.2 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 2250
|
12.1 USD |
|
1 year ago
Aug 10, 2023
|
Sell 982 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 74625
|
13.16 USD |
|
1 year ago
Aug 11, 2023
|
Sell 976 K
USD
|
Rodman David Malcom
Chief Medical Officer
|
- 76182
|
12.81 USD |
|
1 year ago
Aug 11, 2023
|
Bought
25.8 K USD
|
Congleton Jon
Chief Executive Officer
|
+ 2000
|
12.89 USD |
|
2 years ago
Feb 14, 2023
|
Bought
5 M USD
|
HBM Healthcare Investments (Cayman) Ltd.
10 percent owner
|
+ 312500
|
16 USD |
|
2 years ago
Feb 14, 2023
|
Bought
2.11 M USD
|
RA CAPITAL MANAGEMENT, L.P.
Director
|
+ 131600
|
16 USD |
|
2 years ago
Feb 14, 2023
|
Bought
17.9 M USD
|
RA CAPITAL MANAGEMENT, L.P.
Director
|
+ 1118400
|
16 USD |
7. News
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025.
globenewswire.com
- 1 week ago
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.
globenewswire.com
- 2 weeks ago
Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend
Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season.
247wallst.com
- 2 weeks ago
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression –
globenewswire.com
- 3 weeks ago
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile –
globenewswire.com
- 1 month ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
247wallst.com
- 1 month ago
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
globenewswire.com
- 1 month ago
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share pursuant to the exercise in full of the underwriters' option to purchase additional shares in connection with Mineralys' recently completed public offering. After giving effect to the sale of these additional shares, the aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $201.2 million. All of the securities sold in the offering were sold by Mineralys.
globenewswire.com
- 2 months ago
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025.
globenewswire.com
- 2 months ago
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.
benzinga.com
- 2 months ago
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public offering price of $13.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about March 13, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 2 months ago
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders.
seekingalpha.com
- 2 months ago
8. Profile
Summary
Mineralys Therapeutics, Inc. MLYS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 958 M
Dividend Yield
0.00%
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Contact
150 N. Radnor Chester Rd., Radnor, PA, 19087
https://mineralystx.com
IPO
Date
Feb. 10, 2023
Employees
51
Officers
Dr. Robert McKean Ph.D.
Senior Vice President of CMC
Dr. David M. Rodman M.D.
Chief Medical Officer
Ms. Sarah Foster
Vice President of Human Resources
Mr. Jon Congleton
President, Chief Executive Officer & Director
Mr. Adam Scott Levy
Chief Financial Officer & Secretary
Mr. Jeffrey N. Fellows
Senior Vice President of Regulatory Affairs
Ms. Danielle Bradbury
Senior Vice President of Quality Assurance
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.
Founder & Executive Director
Ms. Cindy Berejikian
Executive Vice President of Operations
Ms. Jessica Ibbitson
Senior Vice President of Clinical Operations